Of the eighteen patients enrolled in the phase I/II study with CD19 or CD22 positive lymphoma or leukemia, one patient with primary refractory pre-B acute lymphoblastic leukemia achieved complete tumor response after one cycle and two patients with lymphoma experienced partial responses. This evidence concerns the gene CD19 and leukemia.